Molecular Imaging: Page 2

Health Canada clears latest Hermia molecular imaging update

By AuntMinnie.com staff writers

The clearance allows for Hermia's clinical use across Canadian nuclear medicine and theranostics practices.

May 28, 2026

Am 2014 02 11 15 10 50 886 Canadian Flag 200 (1)

FDG-PET/CT predicts outcomes in patients with HCC

Elevated FDG uptake was consistently associated with poorer overall survival.

May 22, 2026

A graphical abstract of the study.

AuntMinnieEurope Molecular Imaging Insider

By Claudia Tschabuschnig

This edition covers the latest in PET/CT quality assurance, theranostics pipeline updates, AI in nuclear medicine, and policy developments shaping the field across Europe.

May 6, 2026

How AI can help with PET/CT guideline deviations

By Claudia Tschabuschnig

Researchers have found a gap between what international PET/CT guidelines recommend and what actually happens in clinical practice.

May 6, 2026

Pet Ct Scan Fusion Image

The EANM joins EMUC26 and pushes its policy agenda in Brussels

By Claudia Tschabuschnig

Decisions shaping who gets access to theranostics in Europe have long been made mainly in the clinic. With EANM opening a Brussels office and joining EMUC26 as co-organizer, a full policy agenda arrives at the EU table.

May 5, 2026

Serac highlights study on 99mTc-maraciclatide for endometriosis care

By AuntMinnie.com staff writers

Serac Healthcare is highlighting success from a study that evaluated the company's gamma-emitting radiotracer, 99mTc-maraciclatide.

April 30, 2026

Endometriosis 3 D Illustration 400

Lu-177 PSMA-SPECT/CT predicts survival in mCRPC

Lu-177 PSMA-617 SPECT/CT total tumor volume complete response at six weeks associated with overall survival.

April 29, 2026

Quantification of total tumor volume (TTV) at lutetium-177 prostate-specific membrane antigen (PSMA)–617 SPECT/CT shows heterogeneous TTV responses between dose 1 (Cycle #1) and dose 2 (Cycle #2) in participants with metastatic castration-resistant prostate cancer. Posttherapy coronal attenuation-corrected noncontrast SPECT/CT maximum intensity projection images demonstrate (A) near-complete response in a 76-year-old man, (B) complete response in an 83-year-old man, (C) partial TTV reduction (not complete response) in a 69-year-old man, and (D) TTV increase (i.e. progressive disease) in a 74-year-old man. Blue-shaded regions represent semiautomatically segmented PSMA-avid tumor volume, with associated TTV values given at the bottom of each panel. The gradient bar shows standardized uptake value (SUV) from 0 to 5.

ChatGPT matches nuclear medicine experts on FDG-PET/CT scans

Models excelled on cases with well-defined metabolic patterns, such as in typical cases of Alzheimer's disease, yet were less accurate on complex cases.

April 24, 2026

TAG1, NRG Pallas to advance Pb-212 supply for cancer therapies

By AuntMinnie.com staff writers

TAG1 and NRG Pallas aim to develop access to lead-212 (Pb-212) for cancer drug development across Europe.

April 22, 2026

A Rk Nx1 Fop15 Je H Jffj8rq D13

PET links brain metabolism to survival in lung cancer patients

Low brain metabolic activity was associated with increased mortality in patients with advanced NSCLC.

April 9, 2026

A visual abstract of the study

Lu-177 supply chain gets boost with NRG Pallas, Morpho partnership

By AuntMinnieEurope.com staff writers

Firms target early 2027 for Initial commercial delivery.

April 3, 2026

Atom Nuclear Lab Thumb

New recommendations issued on tau PET imaging

By AuntMinnie.com staff writers

Standardized imaging procedures are essential to facilitate the integration of tau PET into clinical workflows.

March 31, 2026

Examples of tau PET patterns in atypical AD and 4R tauopathies. Three axial slices upon MRI or MRI template show radiotracer distribution in exemplary cases of atypical AD and progressive supranuclear palsy (PSP).

Page 2 of 127